Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 4 de 4
Filtrar
Más filtros

Bases de datos
Tipo del documento
País de afiliación
Intervalo de año de publicación
1.
Ann Hepatol ; 17(5): 871-879, 2018 Aug 24.
Artículo en Inglés | MEDLINE | ID: mdl-30145563

RESUMEN

INTRODUCTION AND AIM: We sought to identify independent risk factors for cirrhosis in HFE p.C282Y homozygotes in a cross-sectional study. MATERIAL AND METHODS: We evaluated 368 p.C282Y homozygotes who underwent liver biopsy and compared characteristics of those with and without cirrhosis. We performed multivariable logistic regression on cirrhosis with: age; sex; race/ethnicity; diabetes; blood pints/units donated voluntarily; erythrocyte pints/units received; iron supplement use; alcohol intake, g/d; body mass index, kg/m2; swollen/tender 2nd/3rd metacarpophalangeal joints; elevated alanine aminotransferase; elevated aspartate aminotransferase; steatosis/fatty liver; iron removed by phlebotomy, g; and GNPAT p.D519G positivity. RESULTS: Mean age of 368 participants (73.6% men) was 47 ± 13 (standard deviation) y. Cirrhosis was diagnosed in 86 participants (23.4%). Participants with cirrhosis had significantly greater mean age, proportion of men, diabetes prevalence, mean daily alcohol intake, prevalence of swollen/ tender 2nd/3rd metacarpophalangeal joints, mean serum ferritin, elevated alanine aminotransferase, elevated aspartate aminotransferase, and mean iron removed; and significantly fewer mean blood pints/units donated. GNPAT p.D519G positivity was detected in 82 of 188 participants (43.6%). In a multivariable model for cirrhosis, there were four significant positive associations: age (10-y intervals) (odds ratio 2.2 [95% confidence interval 1.5, 3.3]); diabetes (3.3; [1.1, 9.7]); alcohol intake (14 g alcohol drinks/d) (1.5 [1.2, 1.8]); and iron removed, g (1.3 [1.2, 1.4]). There was no statistical evidence of two-way interactions between these variables. CONCLUSION: In conclusion, cirrhosis in HFE p.C282Y homozygotes is significantly associated with age, diabetes, daily alcohol intake, and iron removed by phlebotomy, taking into account the effect of other variables.


Asunto(s)
Proteína de la Hemocromatosis/genética , Hemocromatosis/genética , Homocigoto , Cirrosis Hepática/genética , Mutación , Aciltransferasas/genética , Adulto , Factores de Edad , Consumo de Bebidas Alcohólicas/efectos adversos , Consumo de Bebidas Alcohólicas/epidemiología , Australia/epidemiología , Comorbilidad , Estudios Transversales , Diabetes Mellitus/epidemiología , Femenino , Predisposición Genética a la Enfermedad , Hemocromatosis/diagnóstico , Hemocromatosis/epidemiología , Hemocromatosis/terapia , Humanos , Cirrosis Hepática/epidemiología , Cirrosis Hepática/patología , Masculino , Persona de Mediana Edad , Fenotipo , Flebotomía , Polimorfismo de Nucleótido Simple , Prevalencia , Medición de Riesgo , Factores de Riesgo , Estados Unidos/epidemiología
2.
Blood Cells Mol Dis ; 63: 15-20, 2017 03.
Artículo en Inglés | MEDLINE | ID: mdl-27936396

RESUMEN

BACKGROUND: GNPAT p.D519G positivity is significantly increased in HFE p.C282Y homozygotes with markedly increased iron stores. We sought to determine associations of p.D519G and iron-related variables with iron stores in p.C282Y homozygotes. METHODS: We defined markedly increased iron stores as serum ferritin >2247pmol/L (>1000µg/L) and either hepatic iron >236µmol/g dry weight or iron >10g by induction phlebotomy (men and women). We defined normal or mildly elevated iron stores as serum ferritin <674.1pmol/L (<300µg/L) or either age≥40y with iron ≤2.5g iron by induction phlebotomy or age≥50y with ≤3.0g iron by induction phlebotomy (men only). We compared participant subgroups using univariate methods. Using multivariable logistic regression, we evaluated associations of markedly increased iron stores with these variables: age; iron supplement use (dichotomous); whole blood units donated; erythrocyte units received as transfusion; daily alcohol consumption, g; and p.D519G positivity (heterozygosity or homozygosity). RESULTS: The mean age of 56 participants (94.6% men) was 55±10 (SD) y; 41 had markedly increased iron stores. Prevalences of swollen/tender 2nd/3rd metacarpophalangeal joints and elevated aspartate or alanine aminotransferase were significantly greater in participants with markedly increased iron stores. Only participants with markedly increased iron stores had cirrhosis. In multivariable analyses, p.D519G positivity was the only exposure variable significantly associated with markedly increased iron stores (odds ratio 9.9, 95% CI [1.6, 60.3], p=0.0126). CONCLUSIONS: GNPAT p.D519G is strongly associated with markedly increased iron stores in p.C282Y homozygotes after correction for age, iron-related variables, and alcohol consumption.


Asunto(s)
Aciltransferasas/genética , Proteína de la Hemocromatosis/genética , Hierro/metabolismo , Mutación Missense , Aciltransferasas/metabolismo , Adulto , Factores de Edad , Anciano , Consumo de Bebidas Alcohólicas , Femenino , Proteína de la Hemocromatosis/metabolismo , Homocigoto , Humanos , Masculino , Persona de Mediana Edad
3.
Lancet ; 388(10045): 706-16, 2016 Aug 13.
Artículo en Inglés | MEDLINE | ID: mdl-26975792

RESUMEN

Haemochromatosis is now known to be an iron-storage disease with genetic heterogeneity but with a final common metabolic pathway resulting in inappropriately low production of the hormone hepcidin. This leads to increase in intestinal absorption and deposition of excessive amounts of iron in parenchymal cells which in turn results in eventual tissue damage and organ failure. A clinical enigma has been the variable clinical expression with some patients presenting with hepatic cirrhosis at a young age and others almost asymptomatic for life. Research is unravelling this puzzle by identifying environmental factors-especially alcohol consumption-and associated modifying genes that modulate phenotypic expression. A high index of suspicion is required for early diagnosis but this can lead to presymptomatic therapy and a normal life expectancy. Venesection (phlebotomy) therapy remains the mainstay of therapy, but alternative therapies are the subject of current research.


Asunto(s)
Consumo de Bebidas Alcohólicas/efectos adversos , Pruebas Genéticas , Hemocromatosis , Hepcidinas/deficiencia , Hierro/metabolismo , Hígado/metabolismo , Mutación , Flebotomía , Proteínas de Transporte de Catión/genética , Manejo de la Enfermedad , Exposición a Riesgos Ambientales , Europa (Continente)/epidemiología , Ferritinas/sangre , Genotipo , Hemocromatosis/diagnóstico , Hemocromatosis/genética , Hemocromatosis/fisiopatología , Hemocromatosis/terapia , Proteína de la Hemocromatosis , Antígenos de Histocompatibilidad Clase I/genética , Humanos , Hígado/efectos de los fármacos , Hepatopatías/etiología , Hepatopatías/fisiopatología , Hepatopatías/terapia , Tamizaje Masivo/métodos , Tamizaje Masivo/normas , Proteínas de la Membrana/genética , Fenotipo , Polimorfismo de Nucleótido Simple , Receptores de Transferrina/genética , Factores de Riesgo , Factores Sexuales , Incertidumbre , Población Blanca/genética
4.
Alcohol ; 30(2): 131-6, 2003 Jun.
Artículo en Inglés | MEDLINE | ID: mdl-12957297

RESUMEN

The close association of excessive alcohol consumption and clinical expression of hemochromatosis has been of widespread interest for many years. In most populations of northern European extraction, more than 90% of patients with overt hemochromatosis are homozygous for the C282Y mutation in the HFE gene. Nevertheless, the strong association of heavy alcohol intake with the clinical expression of hemochromatosis remains. We (individually or in association with colleagues from our laboratories) have performed three relevant studies in which this association was explored. In the first, performed in 1975 before the cloning of the HFE gene, the frequency of clinical symptoms and signs was compared in patients with classical hemochromatosis who consumed 100 g or more of alcohol per day versus in nondrinkers or moderate drinkers who consumed less than 100 g of alcohol per day. The results showed no difference between the two groups except for features of complications of alcoholism in the first group, especially jaundice, peripheral neuritis, and hepatic failure. Twenty-five percent of those with heavy alcohol consumption showed histologic features of alcoholic liver disease (including cirrhosis) together with heavy iron overload. It was concluded that these patients had the genetic disease complicated by alcoholic liver disease. In the second study (2002), 206 subjects with classical HFE-associated hemochromatosis in whom liver biopsy had been performed were evaluated to quantify the contribution of excess alcohol consumption to the development of cirrhosis in hemochromatosis. Cirrhosis was approximately nine times more likely to develop in subjects with hemochromatosis who consumed more than 60 g of alcohol per day than in those who drank less than this amount. In the third study (2002), 371 C282Y-homozygous relatives of patients with HFE-associated hemochromatosis were assessed. Eleven subjects had cirrhosis on liver biopsy and four of these drank 60 g or more of alcohol per day. The reason why heavy alcohol consumption accentuates the clinical expression of hemochromatosis is unclear. Increased dietary iron or increased iron absorption is unlikely. The most likely explanation would seem to be the added co-factor effect of iron and alcohol, both of which cause oxidative stress, hepatic stellate cell activation, and hepatic fibrogenesis. In addition, the cumulative effects of other forms of liver injury may result when iron and alcohol are present concurrently. Clearly, the addition of dietary iron in subjects homozygous for hemochromatosis would be unwise.


Asunto(s)
Hemocromatosis/complicaciones , Hepatopatías Alcohólicas/complicaciones , Alcoholismo/complicaciones , Biopsia , Clonación Molecular , Suplementos Dietéticos/efectos adversos , Etanol/administración & dosificación , Expresión Génica/efectos de los fármacos , Hemocromatosis/genética , Proteína de la Hemocromatosis , Antígenos de Histocompatibilidad Clase I/genética , Homocigoto , Humanos , Hierro/administración & dosificación , Hierro/efectos adversos , Hierro/análisis , Hígado/química , Hígado/patología , Cirrosis Hepática/patología , Hepatopatías Alcohólicas/patología , Proteínas de la Membrana/genética , Mutación , Linaje
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA